CVS Health: The Breakup Puts A Price On The Pharmacy

CVS Health plans to separate its pharmacy and health services businesses into two public companies by the first half of 2028 through a tax-free transaction. The article estimates intrinsic value at $90–$100 per share, 13–25% above current levels, and cites 2026 adjusted EPS guidance of at least $8.20 and a 2027 floor of $8.65. CVS also resumed buybacks, with $11.5B authorized.

Analysis

The potential value unlock is conditional, not automatic: separating pharmacy from health services may improve segment transparency and let investors value distinct earnings streams, but it could also weaken purchasing leverage and coordination across the businesses. The key swing factors are which entity retains debt, how much corporate overhead becomes stranded, and whether each company can sustain cash generation independently. Those details matter more to realized value than a headline sum-of-the-parts estimate.

The stated EPS floors could support a re-rating only if they convert into free cash flow after restructuring and separation costs. Likewise, an authorization is not a commitment: buybacks create more value if executed below intrinsic value, but could compete with deleveraging or separation funding. With the transaction years away, execution and disclosure risk can keep a conglomerate discount in place even if near-term guidance holds. The thesis weakens if guidance is cut, cash conversion disappoints, or separation disclosures show material dis-synergies, unfavorable debt allocation, or significant stranded costs.

Key Decisions for Investors

• Treat CVS as a conditional SOTP opportunity, not a completed catalyst. Consider scaling into a long only if the market price offers a meaningful discount to independently refreshed segment valuations; the article provides no current price or valuation inputs to set an entry level.
• Over the next 1–3 months, monitor segment-level cash flow, debt allocation, stranded-cost estimates, and buyback execution—not just adjusted EPS guidance. These are the missing data most likely to determine whether separation creates value.
• For a 6–18 month thesis, require evidence that the EPS floors translate into free cash flow and that standalone pharmacy and health-services economics remain viable. Reassess if guidance is reduced or reported cash conversion materially trails adjusted earnings.
• Do not pay the full prospective separation premium today: the stated 1H 2028 timetable leaves room for delays, tax-treatment or execution issues, and lost operating synergies. A delay or adverse separation terms would be a clear thesis-negative catalyst.